Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06643780
PHASE4

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis

Sponsor: Prince of Wales Hospital, Shatin, Hong Kong

View on ClinicalTrials.gov

Summary

The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.

Official title: RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis: a Randomized, Double-blind, Double-dummy, Active-Controlled Trial

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-04-09

Completion Date

2027-10

Last Updated

2024-10-16

Healthy Volunteers

No

Interventions

DRUG

Denosumab

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

DRUG

Zolendronic Acid

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

Locations (1)

The Chinese University of Hong Kong

Hong Kong, China